PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)

Detalles Bibliográficos
Autores principales: Sharman, J. P., Jurczak, W., Coombs, C. C., Hill, M., Wang, D., Ku, N. C., Guntur, A., Shahda, S., Leow, C. C., Ghia, P., Mato, A. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429640/
http://dx.doi.org/10.1097/01.HS9.0000850308.96349.64
_version_ 1784779518691508224
author Sharman, J. P.
Jurczak, W.
Coombs, C. C.
Hill, M.
Wang, D.
Ku, N. C.
Guntur, A.
Shahda, S.
Leow, C. C.
Ghia, P.
Mato, A. R.
author_facet Sharman, J. P.
Jurczak, W.
Coombs, C. C.
Hill, M.
Wang, D.
Ku, N. C.
Guntur, A.
Shahda, S.
Leow, C. C.
Ghia, P.
Mato, A. R.
author_sort Sharman, J. P.
collection PubMed
description
format Online
Article
Text
id pubmed-9429640
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94296402022-08-31 PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS) Sharman, J. P. Jurczak, W. Coombs, C. C. Hill, M. Wang, D. Ku, N. C. Guntur, A. Shahda, S. Leow, C. C. Ghia, P. Mato, A. R. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429640/ http://dx.doi.org/10.1097/01.HS9.0000850308.96349.64 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Sharman, J. P.
Jurczak, W.
Coombs, C. C.
Hill, M.
Wang, D.
Ku, N. C.
Guntur, A.
Shahda, S.
Leow, C. C.
Ghia, P.
Mato, A. R.
PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
title PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
title_full PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
title_fullStr PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
title_full_unstemmed PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
title_short PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
title_sort pb1864: bruin cll-321: a phase 3 open-label, randomized study of pirtobrutinib vs investigator’s choice of idelalisib+rituximab or bendamustine+rituximab in btki pretreated cll/sll (trial in progress)
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429640/
http://dx.doi.org/10.1097/01.HS9.0000850308.96349.64
work_keys_str_mv AT sharmanjp pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress
AT jurczakw pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress
AT coombscc pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress
AT hillm pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress
AT wangd pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress
AT kunc pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress
AT guntura pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress
AT shahdas pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress
AT leowcc pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress
AT ghiap pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress
AT matoar pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress

Ejemplares similares